Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. Vertex's gene-editing therapy for sickle cell ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

Slow beginnings for new medicines, especially ones as complex as Casgevy and Lyfgenia, aren’t anything new in the pharmaceutical industry. But the plodding uptake over the therapies’ first ...

The two new therapies—Vertex Pharmaceuticals’ Casgevy and BlueBird Bio’s Lyfgenia—offer the 100,000 Americans and nearly 8 million people globally who suffer from sickle cell potential ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...

Casgevy, developed with Vertex Pharmaceuticals ... Furthermore, Bluebird's Lyfgenia, which treats SCD, costs $3.1 million in the U.S. -- and comes with a warning for blood cancer.

Casgevy, a once-and-done treatment for sickle ... Bluebird bio's gene therapies Zynteglo and Lyfgenia were recently approved to treat beta-thalassemia and sickle cell disease, respectively.

The deal is notable because the U.K.’s cost-effectiveness watchdog initially raised concerns about the durability of the treatment, called Casgevy, in a preliminary ruling last year, saying it ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...